Context Therapeutics Announces Acceptance of Abstract to be Presented at the SITC’s 38th Annual Meeting

Context Therapeutics

PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.

Details of the presentation are as follows:

Title: Development of CTIM-76, a highly specific Claudin 6 bispecific antibody
Abstract Number: 1183
Presenter: Joseph Rucker, Ph.D., Integral Molecular
Date and Time: Friday, November 3, 2023, 9:00 a.m. – 7:00 p.m. PT
Location: Exhibit Halls A and B1, San Diego Convention Center

For more information and to view the abstract, visit the SITC 38th Annual Meeting website.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  Five Below Reports Solid Growth in Q3 2023, Forecasts Promising Outlook for Fiscal Year End